Advertisement

Here's Why Arbutus Biopharma Fell Today

Here's Why Arbutus Biopharma Fell Today

Shares of Arbutus Biopharma (NASDAQ: ABUS) are down 15% at 2:14 p.m. EDT, following the release of the biotech's first-quarter results, although there didn't appear to be anything in the press release to justify the sell-off. Arbutus is still a clinical-stage biotech, so revenue is minimal and comes from collaborations and licenses. The company also has some noncash royalty revenue that it books each quarter.